Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Artem Minalyan, MD, DABOM AMinalyan
3 months 2 weeks ago
Isolated ⬆️ serum #IgG4 level:
💎💎💎 (Dr. Stone):
❓How high? >5x ULN ➡️PPV 75%‼️
❓Typical organ(s) involved?
❓Another explanation?
#eular2024
#rheumx
@eular_org
@RheumNow https://t.co/pm6wjvi2Vt
Bella Mehta bella_mehta
3 months 2 weeks ago
Different clusters - subpopulations of Sjogrens syndrome may exist and getting patient input is important @RheumNow https://t.co/7v5MYzzotT
Bella Mehta bella_mehta
3 months 2 weeks ago
How to assess treatment in Sjogren's Syndrome
#EULAR2024 @RheumNow
1) define the target population
2) standardize inclusion criteria
3) Restricting ESSDAI domain to 5 domains
4) Correct endpoint choice https://t.co/m7DvZdpuZa
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 POS0223 UK multicentre data showed real-world avacopan use in #vasculitis differed from RCT: it was started later;often combined w other IS; GC tapering varied; 20% had eGFR<15. Compared to historical cohort of GC taper, OR of clinical response in AVA was 3.6 @RheumNow https://t.co/MP3OrRSJ0U
Bella Mehta bella_mehta
3 months 2 weeks ago
Sjogrens Syndrome - bench to bedside session.
#EULAR2024 @RheumNow
Important to concentrate on non infiltrative patients. (to find different / early phenotypes?) https://t.co/ezFkX6CW8l
Bella Mehta bella_mehta
3 months 2 weeks ago
Real world data of safety profiles in SpA and Secukinumab- in all age groups #POS0199 #EULAR2024 @RheumNow https://t.co/q0FFP2SMLl
Bella Mehta bella_mehta
3 months 2 weeks ago
Very contradictory study in Axial SpA- no evidence of better drug retention or better treatment response compared to a later start of treatment.
Data of early and very early disease. POs0204 #EULAR2024 @RheumNow https://t.co/6ci6xfyRmq
David Liew drdavidliew
3 months 2 weeks ago
What happens when RA patients only on csDMARDs want to stop their meds?
in BIO-FLARE, only half flared within 6mo of stopping all csDMARDs suddenly. They’ve got a clinical predictive model. Many milder patients ask, and could benefit!
#EULAR2024 POS0068 John Isaacs @RheumNow https://t.co/B7ZjP5Pj70
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 OP0206 In a cohort study, of pts with #lupus nephritis, 81% tapered IS ~32 mths post-renal response. Of this, 17% flared. Strategies for safe tapering: ensure CR is achieved, low SLEDAI-2K at 12mths, low SLEDAI-2K & on HCQ at the time of tapering initiation @RheumNow https://t.co/hAMAdsL7Jn
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Risk of developing RA increased in antibody double-positive and single-positive compared to seronegative individuals. Highest risk in double-positive in first year. Single-positive increased risk of RA for up to five years after testing. In double-positive the risk remained… https://t.co/XLDHK4d4AE https://t.co/3Ek8knGExU
David Liew drdavidliew
3 months 2 weeks ago
Biosimilar uptake across the world.
Interesting that rich countries use more biosimilars - presumably because they have bargaining power - and that means they can access even better pricing.
#EULAR2024 POS0597 Leiden @RheumNow https://t.co/wZgA0JH5uu
David Liew drdavidliew
3 months 2 weeks ago
Still a long way but fascinating re: computer vision of hand movement from @vincevenerito @ThomasHugle.
Proof of concept training set shows decent correlation with DAS28-LDA & HAQ-DI. Much more work needed but the promise for telehealth is enticing
#EULAR2024 POS0607 @RheumNow https://t.co/iXsdn9fvuH
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
Swedish/Danish cohort study in PsA
17000+ bionaïve 8000+ TNFi & 2000+ other MoA
Overall non melanoma skin cancer rate 651
(505 BCC & 87 SCC)
TNFi treated pts:
HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50)
HR 1.19 NMSC vs. other MoA (ns)
#EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6
David Liew drdavidliew
3 months 2 weeks ago
“One way to get rid of TDM is to get more drugs, and that’s what we’re doing”
- Gertjan Wolbink, the godfather of rheumatology therapeutic drug monitoring (TDM)
#EULAR2024 @RheumNow https://t.co/SYM8hjMMPJ
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
TYK2i RCT 290 pts 12 wks in active PSA
TAK-279 15mg 30 mg 53% 54% vs PBO 29%
ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15%
Safety profile acceptable
Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp
